Work

Ketosis and neuroprotection: a systematic review of randomised controlled trials assessing the effects of diet-induced ketosis in neurodegenerative disorders

Year: 2026
Type: review
Study design: Systematic Review
Abstract: Introduction: Neurodegenerative Diseases (NDDs) are complex in aetiology and progressive in pathophysiology.Their pathology is attributed to the loss of neurons and synaptic connections due to mitochondrial dysfunctions, oxidative stress, protein aggregation and neuroinflammation.The most common NDDs are Alzheimer's Disease (AD), Parkinson's Disease (PD) and Multiple Sclerosis (MS).The ketogenic Diet (KD) is a dietary model that mostly includes dietary fat.KD has been seen to positively affect multiple neurological disorders, including epilepsy, cerebral ischemia and NDDs.Aims: The study aims to systematically review all existing randomised clinical trials (RCTs) assessing the efficacy of nutritional ketosis intervention in patients diagnosed with Alzheimer's disease, Parkinson's disease and Multiple Sclerosis.Methodology: A comprehensive search along two databases (PubMed and Scopus) was conducted for RCTs evaluating the effects of KD and/or nutrition-induced ketosis in patients diagnosed with AD, PD or MS.The search was concluded by 31/01/2026 and included studies published from 01/01/2015 onwards.The systematic review was conducted in accordance with the PRISMA guidelines.The risk of bias assessment was performed using the Cochrane Risk of Bias Tool 2 (RoB2).Results: A total of 18 RCTs that fulfilled all the eligibility criteria were included in the systematic review; 8 for AD, 4 for PD and 6 for MS (851, 97 and 287 patients, respectively).In AD, ketogenic interventions significantly improved QoL in APOE4(+) carriers (p=0.042)(Henderson et al., 2020), cognition in APOE4(-) patients (ADAS-Cog-C: +2.62 vs -2.57, p<0.01) (Xu et al., 2020), logical memory and digital-Symbol scores (Ota et al., 2019).In PD, significant improvements were found in non-motor symptoms (MSD-UPDRS Part I: -4.58 vs -0.99, p<0.001) (Phillips et al., 2018); lexical access (p=0.02) and memory performance (p=0.01)(Krikorian et al., 2019).In MS, significant findings included improvement in depressive symptoms (p<0.045)(Platero et al., 2021), Institutional Repository -Library & Information Centre -University of Thessaly 16/09/2026 14:17:52 EEST -64.87.45.37 improved QoL (p<0.05)(Bock et al., 2015), and reduced pro-inflammatory ALOX5 expression, correlated with QoL scores (p=0.045/0.012)(Bock et al., 2018).Discussion: Ketogenic interventions consistently induced ketosis and improved non-motor, cognitive, and biomarker outcomes, but effects on primary disease-defining endpoints were inconsistent across trials.Heterogeneity in intervention type, duration, and outcome measures, alongside generally unclear risk of bias, limits the strength of these findings.More research is needed for KD to be confidently recommended alongside traditional treatments.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7213379356
FWCI:
Cites: 129
Cited by:
Related to: 10